Overview

Taxotere-Enoxaparin-(ENOXA)-Study

Status:
Terminated

Trial end date:
2011-02-01

Target enrollment:

Participant gender:

Summary

Taxotere-Enoxaparin-(ENOXA)-Study: 1st-Line Docetaxel-Platin Chemotherapy as single therapy or in combination with Enoxaparin in patients aged older than 18 years with locally advanced or metastatic non-small cell lung cancer (stadium IIIb/IV), a phase III study. Study hypothesis: Increase of progressive free survival from 5 to 7.5 months.

Phase:

Phase 3

Details

Lead Sponsor:

Hannover Medical School

Collaborator:

Hannover Clinical Trial Center GmbH

Treatments:

Docetaxel
Enoxaparin
Enoxaparin sodium